AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: cancer

newssourceFORcompanyinformationcontent1releasesmarket

The Jackson Laboratory secures grant from The Michael J. Fox Foundation to advance Parkinson’s disease research through the JAX-NYSCF Collaborative

New human stem cell platform will expand access to standardized disease models, support Parkinson's disease research and therapeutic discovery efforts NEW YORK , June 9,...

Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham 

- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma

- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...

Strong Indonesian Demand Reinforces Malaysia Healthcare’s Growth at Malaysia Fair 2026

JAKARTA, Indonesia, June 9, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC), together with Tourism Malaysia, recorded strong visitor engagement at Malaysia Fair Jakarta 2026,...

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...

Foresee’s Oral ALDH2 Activator, Mirivadelgat to Enter Clinical Testing in Parkinson’s Disease in the SLEIPNIR Phase 2a Platform Trial

TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas 
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers